GO
Loading...

Medicine

More

  • Pfizer's CEO Kindler Being Kind To Hillary--Again Monday, 25 Feb 2008 | 1:37 PM ET

    According to The Center for Responsive Politics' web site Pfizer Chairman and CEO Jeff Kindler has opened his wallet again for Sen. Hillary Clinton. You can see his latest "give" here. Twice now within the past year Kindler has given the maximum amount ($2,300) an individual can contribute to a candidate.

  • Genentech: How It Got Its Groove Back Monday, 25 Feb 2008 | 10:42 AM ET

    I always prefer it when pharmaceutical/biotech execs and analysts can break out of their scientific/financial jargon and give good soundbites or quotes. So, among the flurry of research notes I've received over the weekend and this morning on the Genentech Avastin news the award goes to Rodman & Renshaw's Mike King who writes, "The biotech leader has its groove back."

  • Genentech's Avastin Gets "Qualified" Win From FDA Friday, 22 Feb 2008 | 4:53 PM ET

    Shortly before the closing bell trading in shares of Genentech was halted for news pending. Then, right after the bell the company issued this press release announcing the Food and Drug Administration has granted "accelerated approval" to Genentech's Avastin for use on breast cancer.

  • Waiting For FDA--In the Meantime, Your Emails Friday, 22 Feb 2008 | 12:03 PM ET

    As we sit here closely monitoring the wires and waiting for word out of Genentech and/or the FDA about a decision on Avastin for breast cancer, it seemed like as good a time as any to once again post some samples of a flood of recent emails from readers--the good, the bad and the ugly.

  • Merck, SGP's "Enhance" Study No "Late Breaker" At ACC Thursday, 21 Feb 2008 | 4:36 PM ET

    The results of the controversial study called "Enhance" of the cholesterol drug Vytorin from Merck and Schering-Plough will not be presented as a prestigious "late breaker" at the upcoming annual meeting of the American College of Cardiology.

  • Genentech's Avastin: Will FDA Give It An "Oscar"? Thursday, 21 Feb 2008 | 11:25 AM ET

    Who needs Oscar ballots? Biotech investing wonks/nerds (and I'm not suggesting I am one) might wanna start an office pool about when and what the FDA's decision will be on Genentech's drug Avastin for breast cancer.

  • Pfizer Wheelin' and Dealin' For Encysive's Thelin Wednesday, 20 Feb 2008 | 10:54 AM ET

    The world's biggest drug company is spending chump change to take out a little biotech at a 118 percent premium. Pfizer, which has a cash hoard of more than $20 billion, is plunking down a paltry (for Pfizer, that is) $195 million in cash money to buy Encysive Pharmaceuticals.

  • Black Tuesday for Onyx Tuesday, 19 Feb 2008 | 12:27 PM ET

    Almost exactly one year since Onyx Pharmaceuticals announced positive results of its drug Nexavar for liver cancer and the stock doubled in one day, the biopharmaceutical company is providing an example of the ups and downs of drug development and biotech investing.

  • Hedge Fund Gets Back To Me On Dendreon Holdings Friday, 15 Feb 2008 | 3:19 PM ET

    Even though I'm off today I, like a lot of folks, couldn't help checking my landline voicemail at work. And much to my surprise one of the messages was from Mark Gottlieb, the Chief Compliance Officer at Visium Asset Mgt. I referred to him in yesterday's post.

  • Genentech, JNJ, Pfizer: Big Days Ahead For Pharma Friday, 15 Feb 2008 | 9:41 AM ET

    Taking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.

  • Dendreon Getting "The Love" From Investors Thursday, 14 Feb 2008 | 4:34 PM ET

    Early today a press release and headlines were crossing the wires about Dendreon announcing positive test results on its controversial prostate cancer drug, Provenge, at an oncology conference in San Francisco.

  • Chantix Article Author Interview Touches Nerve Thursday, 14 Feb 2008 | 11:43 AM ET

    This morning we did back-to-back interviews on "Squawk Box" with the author of the New York Magazine article about his experience on the smoking cessation drug Chantix and a PfizerĀ  exec to respond to it. You can watch the segment in the video clip.

  • Dendreon/Provenge Saga: There Is News After All Thursday, 14 Feb 2008 | 11:32 AM ET

    Not long after I submitted my last post I got word that the House Energy and Commerce Committee sent a letter today to the four Congressmen who had requested a hearing into the Dendreon/Provenge saga. And the answer is "no." The stock, which had been rallying on heavy volume today, sank when we broke the news on "Closing Bell."

  • There was a mini-rally and spike in volume in shares of good ol' Dendreon this morning and early afternoon. The run-up occured ahead of CEO Dr. Mitchell Gold's presentation at the BIO CEO conference in New York City at 1:15 ET.

  • Genentech's Avastin Study: Will It Help Get FDA Approval? Wednesday, 13 Feb 2008 | 10:29 AM ET

    After the closing bell yesterday Genentech popped out a stock-moving press release. The world's most highly-valued biotech announced that its drug Avastin when used in combo with Sanofi-Aventis' chemo drug, Taxotere, helped women with a certain type of aggressive, advanced breast cancer live longer without the disease getting worse.

  • The current issue (February 18, 2008) of New York Magazine has a story that it teases on the cover above the masthead, "No Smoking Wonder Drug." Below it in drug-label fine print the sub-head is: "Makes quitter talk to potted plants."

  • Schering-Plough is bringing up the rear of big pharma earnings season this morning--it reported later than normal because it apparently took longer to do all the accounting for a big acquisition--with a beat on the top and bottom line. But investors, as is usually the case, are more concerned about guidance.

  • Allergan "Suffering" From Adverse Botox Events Friday, 8 Feb 2008 | 4:46 PM ET

    Shares of Allergan are taking a big hit today after the Food and Drug Administration announced it's putting out an "Early Communication" (Translation: We're reviewing some reports of adverse events, but in the meantime, doctors and patients should be vigilant) regarding potentially fatal side effects of the popular muscle relaxant Botox.

  • Glaxo's Avandia Hits The Bottom Line--Hard Thursday, 7 Feb 2008 | 12:43 PM ET

    Shares of GlaxoSmithKline this morning are getting hammered because the company announced it expects earnings per share to fall by a mid-single digit percentage this year. Analysts thought they'd grow by three percent.

  • Diabetes Drug Safety: Has Another Red Flag Been Raised? Wednesday, 6 Feb 2008 | 3:07 PM ET

    Reaction to part of a big government-sponsored diabetes drug study being halted over fatalities is pouring in from several corners. The American Diabetes Association put out a press release saying it "strongly encourages people with diabetes not to alter their course of treatment without first consulting with their health care team...